Resultados de Búsqueda

NICE

National Institute for Health and Clinical Excellence (NICE)

Endocuff Vision should be considered as an option for people having a colonoscopy as part of bowel cancer screening following a positive stool test. There is limited evidence for the benefits of Endocuff Vision in a non-screening population. Cost modelling shows that for people having a colonoscopy as part of bowel cancer screening, using Endocuff Vision is cost saving. Savings are related to the adenoma detection rate; for a colonoscopist with a baseline adenoma detection rate of 51%, using ...

NICE

National Institute for Health and Clinical Excellence (NICE)

Only if: - trastuzumab is the only HER2‑directed adjuvant treatment they have had, and - if they had neoadjuvant chemotherapy-based regimens, they still had residual invasive disease in the breast or axilla following the neoadjuvant treatment, and - the company provides neratinib according to the commercial arrangement. This recommendation is not intended to affect treatment with neratinib that was started in the NHS before this guidance was published. People having treatment ...

NICE

Only if: - Exemestane plus everolimus is the most appropriate alternative to a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor and - The conditions in the managed access agreement for palbociclib with fulvestrant are followed. This recommendation is not intended to affect treatment with palbociclib with fulvestrant that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements ...

NICE

National Institute for Health and Clinical Excellence (NICE)

This guidance is not intended to affect adjuvant treatment with pertuzumab that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop. There is uncertainty about the size of the clinical benefit for pertuzumab in the adjuvant treatment of HER2‑positive early ...

NICE

National Institute for Health and Clinical Excellence (NICE)

Palbociclib or ribociclib, taken with an aromatase inhibitor, are usually the first treatments for locally advanced or metastatic, hormone receptor-positive, HER2-negative breast cancer. They are cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors, as is abemaciclib. Clinical trial evidence shows that abemaciclib with an aromatase inhibitor increases how long people live without their disease getting worse, compared with an aromatase inhibitor alone. It is not known whether abemaciclib ...